Women's Longevity: Ovarian Aging, Healthspan, and Female-Specific Anti-Aging

Your Ovaries Are Aging Twice as Fast as the Rest of You

A woman born in the year 2000 can expect to live past 80. Her ovaries, however, will functionally retire around 51. That gap -- roughly three decades of life after ovarian function ceases -- creates a biological mismatch that no other organ system imposes on the body. And the consequences go far beyond fertility.

Ovaries age at almost twice the rate of other tissues in the female body, according to a 2025 review in Genes & Development by Dr. Berenice Benayoun at USC and Dr. Jennifer Garrison at the Buck Institute. That accelerated decline makes the ovary one of the first organs to show functional deterioration, with noticeable changes starting in a woman's late 20s and accelerating sharply after 35.

Dr. Yousin Suh at Columbia University compared ovarian tissue from women in their 20s and late 40s, expecting to find some unique pathology. What she found instead was more surprising. The ovaries were aging through the exact same mechanisms as every other organ -- telomere shortening, mitochondrial dysfunction, cellular senescence, stem cell exhaustion -- but at a dramatically compressed pace. "You don't call a 40-year-old brain an aging brain," Suh told TIME, "but for 40-year-old ovaries, they are already in the nursing home."

Think of the ovary as a biological clock that runs at double speed. While the heart, brain, and kidneys operate on a roughly 80-year timeline, the ovary is sprinting through the same aging program in about half that time. When it stops producing hormones at menopause, the rest of the body feels the sudden silence.

Women live 5-6 years longer than men on average across every country and socioeconomic group -- but spend 25% more years in poor health. Scientists call this the mortality-morbidity paradox.

That paradox may trace directly back to ovarian aging. Late-life changes in ovarian endocrine function are increasingly viewed as the driver. Garrison describes ovaries as "conductors in an orchestra," coordinating bone health, heart health, metabolism, and immune function through hormones and signaling molecules that communicate with nearly every tissue in the female body. When the conductor stops, the orchestra doesn't just play out of tune. Whole sections fall apart.

Postmenopausal women face elevated risk for nearly every chronic age-related disease: osteoporosis, cardiovascular disease, neurodegeneration, type 2 diabetes, and cognitive decline. Menopause itself accelerates biological aging -- meaning epigenetic clocks, which measure how fast cells are aging at the molecular level, tick faster after menopause begins (Levine et al. 2016).

Even the immune system tells a sex-specific story. Immune senescence -- the aging of the immune system itself -- occurs earlier and to a greater extent in men, which partly explains why women have stronger immune responses throughout most of their lives. But after menopause, women's immune advantage erodes, and their rates of autoimmune conditions and inflammatory diseases surge. The practical takeaway: the ovarian clock doesn't just track reproductive decline. It paces systemic aging for the entire female body.

The Numbers Behind Ovarian Reserve: From Seven Million to Fewer Than a Thousand

The math of ovarian aging is staggering. At about 20 weeks of fetal development, a female fetus carries roughly 7 million oocytes -- the peak egg count she will ever have. By birth, that number has dropped to 1-2 million. By puberty, about 400,000 remain. Over the course of her reproductive life, only around 350 of those eggs will actually be ovulated. The rest undergo atresia, a process of natural cell death. By menopause at an average age of 51, fewer than 1,000 primordial follicles persist.

This depletion doesn't follow a straight line. Mathematical models show the decline accelerates sharply around age 30, driven by increased oocyte atresia. The acceleration explains why fertility conversations often fixate on the mid-30s threshold, though the health implications of that decline extend well beyond reproduction.

Anti-Mullerian hormone (AMH) has emerged as the most reliable window into ovarian reserve. Produced by granulosa cells in developing follicles, AMH remains relatively stable across the menstrual cycle, which makes it clinically practical. Research published in MedComm found that AMH outperforms age, antral follicle count, FSH, and inhibin B as a predictor of menopause timing. But AMH isn't just a fertility marker. Declining AMH levels have been linked in emerging clinical studies to increased cardiovascular risk and insulin resistance.

Life Stage	Approximate Oocyte Count	Key Biological Event
20 weeks gestation	~7 million	Peak oocyte count
Birth	1-2 million	Atresia already underway
Puberty	~400,000	Ovulation begins
Age 30	~100,000	Depletion rate accelerates
Age 37-38	~25,000	Rapid acceleration begins
Menopause (~51)	<1,000	Functional cessation

That timeline also has a genetic component. Heritability of the age at natural menopause ranges from 44% to 85%, according to Benayoun and Garrison's review. A major genome-wide association study identified 209 significant genetic loci associated with menopause timing in more than 200,000 European women (Ruth et al. 2021). Many of these genes are involved in DNA damage repair -- the same machinery that protects all cells from aging.

Lifestyle factors also move the needle. Smoking, high-fat diets, and intense physical activity are associated with earlier menopause. Having children appears to slow the process: nulliparity is linked to earlier menopause, while multiparity pushes it later. Women who use oral contraceptives tend to experience later menopause and a longer reproductive span.

About 10% of women naturally enter menopause after age 55, and this group consistently shows better health outcomes and longer lifespans. That pattern has attracted serious research attention: if later ovarian function correlates with longer, healthier life, then interventions that extend ovarian function could be genuine longevity tools rather than fertility treatments dressed up in anti-aging language.

Dr. Francesca Duncan at Northwestern (now also at the Buck Institute) added another dimension to ovarian reserve measurement. Her lab made the fundamental observation that the aging ovary becomes inflammatory, fibrotic, and stiff. She is developing an ultrasound-based test that uses ovarian stiffness as a biomarker, which could eventually complement AMH blood tests with a structural measure of ovarian health.

NAD+ and the Ovarian Energy Crisis

Nicotinamide adenine dinucleotide -- NAD+ -- is involved in more than 500 enzymatic reactions in the human body. It drives energy production in mitochondria, fuels DNA repair, and regulates inflammation. Its decline with age is one of the most consistent findings in aging biology. In ovaries, that decline hits earlier and harder than in most other tissues.

The mechanism works like this: as ovarian cells age, they accumulate DNA damage. Repairing that damage requires activating an enzyme called PARP1, which consumes NAD+ and ATP in the process. This creates a vicious cycle -- more damage means more repair attempts, which drain more NAD+, which compromises the mitochondria that generate cellular energy, which makes cells more vulnerable to further damage.

Running alongside this cycle is CD38, an enzyme whose expression increases with aging in the ovary. CD38 is essentially an NAD+ scavenger -- it breaks down NAD+ as part of its normal function. As CD38 levels rise with age, NAD+ levels drop, and inflammatory gene expression across ovarian cell types increases. In mouse studies, both genetic ablation and chemical inhibition of CD38 counteracted ovarian aging phenotypes (Perrone et al. 2023; Yang et al. 2024).

The parallel to a brownout is useful here. Imagine a building where the generator is getting old (declining NAD+), while the tenants keep plugging in more devices (CD38, PARP1 consuming NAD+). Eventually the power supply can't keep up, and systems start shutting down -- except in this case, the systems are mitochondrial function, DNA repair, and hormonal production.

This has fueled commercial interest in NAD+ precursor supplements, particularly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). A clinical trial found that 1 gram of NR taken daily increased NAD+ levels by approximately 60% in blood cells compared to placebo, with no reported adverse effects. NR has received "Generally Recognised as Safe" status from the FDA.

But the enthusiasm needs tempering. A 2022 review in Antioxidants found that the safety dose, therapeutic window, and optimal treatment duration for NMN and NR remain unestablished. Long-term consequences of chronically elevated NAD+ are unknown. In mice, high-dose NR caused glucose intolerance and white adipose tissue dysfunction. There is also a theoretical concern about cancer promotion, since NAD+ fuels cellular growth and proliferation -- processes that cancer cells exploit.

No human clinical trial has directly tested NAD+ supplementation for ovarian aging. The CD38/NAD+ connection in ovaries has been demonstrated in mice, and the leap from mouse ovary to human ovary is significant.

CD38 inhibition reversed ovarian aging markers in animal models, and the underlying biology -- NAD+ depletion driving mitochondrial dysfunction -- is consistent across aging research. Whether swallowing an NR or NMN capsule delivers enough NAD+ to the right ovarian cells at safe long-term doses is a different question entirely, and one that nobody has answered yet in humans.

Why Zombie Cell Drugs Don't Work the Same in Women

Senolytic drugs -- compounds designed to selectively eliminate senescent "zombie" cells that accumulate with age and spew inflammatory molecules -- are among the most talked-about interventions in longevity research. The logic is straightforward: remove the damaged cells, reduce inflammation, restore tissue function. In several contexts, it works. In ovaries, the story is considerably more complicated.

A 2024 study published in AGE tested the two most commonly used senolytic combinations -- dasatinib plus quercetin (D+Q) and fisetin -- in reproductive-age female mice. The results were clear: neither D+Q nor fisetin improved pregnancy rate, litter size, or ovarian reserve. Fisetin did reduce some senescence markers -- lipofuscin staining decreased (P=0.008) and macrophage infiltration dropped (P=0.002) -- but these biochemical improvements didn't translate into functional benefit.

A separate study in Scientific Reports delivered an even more concerning finding. When researchers gave ABT-263, a potent senolytic that targets the Bcl-2 family of anti-apoptotic proteins, to 16-month-old mice (roughly equivalent to a 45-year-old woman), the drug actually accelerated the depletion of ovarian follicles. It reduced fibrosis and preserved some steroidogenic gene expression, but the net effect was destructive: fewer eggs, not more.

The timing problem is telling. Early intervention with ABT-263 (in younger mice) has been shown to extend reproductive lifespan in other studies. But when given closer to the equivalent of human menopause, the same drug backfires. The likely explanation: by that age, most remaining primordial oocytes are themselves senescent. A drug designed to kill senescent cells will kill the remaining eggs.

Senolytic Approach	Timing	Ovarian Outcome	Source
D+Q (dasatinib + quercetin)	Young mice (1-6 months)	No improvement in reserve or fertility	Garcia et al. 2024
Fisetin	Middle-aged mice (6-10 months)	Reduced some markers, no functional benefit	Garcia et al. 2024
ABT-263	Old mice (16 months, ~45 human years)	Accelerated follicle depletion	Nature Scientific Reports 2024
D+Q	Young females	Increased body weight, fat, senescence markers	Garcia et al. 2024 (citing ref 17)

Sex differences compound the problem. A 2025 review in Frontiers in Aging Neuroscience found that cyclic D+Q treatment improved episodic memory in middle-aged male rats but did not improve cognition in females. The authors identified a fundamental biological tension: estrogen promotes growth, proliferation, and cell survival through gene transcription pathways that operate in a manner opposite to senolytic drugs. Senolytics kill; estrogen protects. In premenopausal women with circulating estrogen, senolytics may be fighting biology rather than working with it.

There is also the awkward fact that ovaries are supposed to be inflammatory. The ovulatory process itself involves tissue remodeling, inflammation, and immune cell activity every month. Senescent cells may play physiological roles in reproductive function that we don't fully understand, and removing them could disrupt normal ovarian cycling.

None of this means senolytics are useless in women's health. Fisetin did reduce macrophage infiltration and some senescence gene expression in ovaries. Senolytics show benefits in women for non-ovarian tissues. The issue is specific: applying zombie-cell drugs to a tissue that's already operating on compressed timelines and depends on inflammatory processes for normal function. The research suggests a more careful approach -- potentially using senolytics in women before significant ovarian aging begins, or targeting non-ovarian senescent cells that contribute to systemic inflammation without touching the ovary directly.

What Actually Works: Interventions From Your 20s Through Postmenopause

The list of female-specific anti-aging interventions is growing, but the evidence behind each one ranges from decades-old clinical trials to mouse studies published last year. Sorting proven from promising from premature matters more than ever when supplements and procedures are already being marketed to women.

Hormone therapy: the intervention with 80 years of data

Menopausal hormone therapy (MHT) remains the most studied intervention for postmenopausal health. After the Women's Health Initiative trial created widespread fear in the early 2000s, more recent analyses have shifted the narrative. When initiated within 10 years of menopause onset, MHT shows a net beneficial effect on cognition, bone density, and cardiovascular risk. The cardiovascular benefit is particularly relevant because standard cardiovascular prophylaxis -- aspirin and statins -- shows minimal efficacy in women compared to men (Ridker et al. 2005; Petretta et al. 2010).

Jennifer Garrison's assessment is blunt: hormone therapy is the "best Band-Aid we have" for menopause-related health risks, but there has been "almost zero innovation in 80 years." The 2026 Global Wellness Summit identified HRT being reframed from menopause symptom relief to potential longevity medicine as a major industry trend. The distinction matters: managing hot flashes is symptom control, but preserving cardiovascular and cognitive function through timely hormone therapy is healthspan extension.

Rapamycin: the drug trial women signed up for overnight

Dr. Zev Williams at the Columbia University Fertility Center is leading VIBRANT, a randomized, placebo-controlled trial in which 50 women take low-dose rapamycin weekly for three months, with nine months of follow-up. Rapamycin works by inhibiting mTOR, a protein involved in cellular aging and metabolic regulation. In preclinical models, mTOR inhibition extends ovarian lifespan by slowing the rate at which follicles activate and die each month.

Williams noted that recruitment was immediate: "The day the study went live, we had over 100 people." While the trial is not yet complete, Williams has reported that in blinded observations, "one group is reporting benefits such as better mood, better memory, and feeling that their skin looks better." Rapamycin is already FDA-approved for other indications and has extensive safety data, which could accelerate its path to clinical use for ovarian aging if results hold.

AMH-based therapies: keeping follicles dormant

Anti-Mullerian hormone does something counterintuitive: it keeps ovarian follicles asleep. By preventing too many follicles from activating at once, AMH slows the rate of depletion. Dr. David Pepin at Mass General and Harvard discovered in 2017 that AMH is effective at stopping follicle growth, and a biotech company (Oviva Therapeutics, acquired by Granata Bio in 2025) is developing an AMH drug. Celmatix Therapeutics is also testing a molecule that closely mimics AMH, with primate trials planned.

Ovarian tissue cryopreservation: banking your biological clock

Fertility specialist Dr. Kutluk Oktay developed an outpatient procedure where ovarian cortex tissue is laparoscopically retrieved, frozen, and later transplanted back when AMH levels signal approaching menopause. About 60% of reserve eggs survive the transplant, with expectations of reaching 80% survival in the future. The key constraint: it should be performed before the rapid acceleration of egg loss, around age 37-38.

Lifestyle interventions: what the evidence supports now

While pharmaceutical approaches are still in clinical trials, certain lifestyle interventions have current evidence behind them. Strength training has been identified as a non-negotiable intervention for women's longevity, with proven effects on bone density preservation, metabolic health, fall prevention, and maintaining independence in later life. This is not aesthetic fitness advice -- it is functional longevity medicine.

Smoking, high-fat Western diets, and extremely intense exercise are associated with earlier menopause. Moderate physical activity, on the other hand, is linked to later menopause. Multiparity and oral contraceptive use also correlate with extended ovarian function. These aren't treatments in the pharmaceutical sense, but they represent modifiable factors that influence the pace of ovarian aging.

Intervention	Evidence Level	Best Window	Status
Hormone therapy (MHT)	Strong (multiple large trials)	Within 10 years of menopause	Available now
Strength training	Strong (broad evidence base)	All life stages	Available now
Low-dose rapamycin	Promising (VIBRANT trial ongoing)	Premenopausal	Clinical trial
AMH-based therapy	Early preclinical	Premenopausal	Animal testing
Ovarian tissue cryopreservation	Experimental	Before age 37-38	Limited clinical use
NAD+ precursors (NR/NMN)	Mechanistic support, no ovarian trials	Unknown	Supplements available, no clinical validation for ovarian aging
Senolytics (D+Q, fisetin)	Mixed/negative for ovarian use	Uncertain	Research stage

Why the Research Gap Is the Real Emergency

The average American woman will spend approximately 25 years in a postmenopausal state. For a woman born in 1900, with an average lifespan of 48 years, menopause was often a non-event. Modern longevity has turned it into a defining health transition -- and one that the medical system is remarkably ill-equipped to handle.

The funding numbers tell the story plainly. In 2023, approximately 2% of all health-related venture capital went to women's health, according to a Deloitte analysis. Clinical trials in the United States were not required to include women until 1993. MIT neuroscientist Frida Polli estimated that less than 10% of clinical and scientific data from the last 100 years comes from female physiology.

The consequences of that data gap are concrete. Aspirin and statins -- standard cardiovascular protection for men -- show minimal efficacy in women. The longevity interventions most commonly discussed in public -- from intermittent fasting protocols to cold exposure routines -- were largely developed from male data. The 2026 Global Wellness Summit flagged a blunt reality: "Men live until 90 with a fully functioning gonad. Women do not." No other biological asymmetry creates such a stark divide in aging trajectories.

There are signs this is changing. The Buck Institute's Center for Healthy Aging in Women has funded 57 research grants across 4 continents since its founding in 2019. XPRIZE is fundraising for a $50 million-plus competition for ovarian health research, targeting a 2026 launch. Nuttall Women's Health Foundation is offering grants up to $5 million for ovarian aging studies.

The reframe gaining ground is simple: menopause is the event people recognize, but ovarian aging is the much longer process underneath it. Managing hot flashes and insomnia is symptom control. Understanding why ovaries age at double speed and what can be done about it is longevity science. The distinction will shape women's health for the next decade.

Even the understanding of what ovaries do after menopause is evolving. When ovaries are surgically removed (as opposed to reaching natural menopause), a woman's risk for chronic conditions including cardiovascular disease exceeds that of naturally postmenopausal women. This suggests that ovaries continue producing something -- androgens, signaling molecules, or other factors -- that protects health even after estrogen production ceases. What that something is, and whether it can be replicated therapeutically, is among the most important open questions in women's longevity research.

Frequently Asked Questions

Can NAD+ supplements slow ovarian aging in women?

There is strong mechanistic evidence that NAD+ depletion contributes to ovarian aging, particularly through the CD38 enzyme pathway. Mouse studies show that blocking CD38 can counteract ovarian aging markers. However, no human clinical trial has tested NAD+ supplementation specifically for ovarian aging. The supplements NR and NMN can raise blood NAD+ levels, but whether they deliver meaningful amounts to ovarian tissue at safe long-term doses is unknown. The target looks real; the delivery mechanism is unproven for this specific application.

Are senolytics safe for women to take?

Current research raises caution flags specific to women. In mouse studies, common senolytics like dasatinib plus quercetin and fisetin failed to improve ovarian function and in some cases worsened outcomes. The ABT-263 senolytic actually accelerated follicle depletion in older mice. Estrogen appears to work through pathways that oppose senolytic mechanisms, creating a fundamental biological tension. Senolytics may benefit other tissues in women, but using them to target ovarian aging specifically is not supported by current evidence.

What is the most important thing women can do now for longevity?

Based on current evidence, three interventions have the strongest support: consistent strength training throughout all life stages (particularly for bone density, metabolic health, and fall prevention), timely hormone therapy discussion with a physician when approaching menopause (ideally within 10 years of onset), and baseline tracking of ovarian health biomarkers like AMH. Avoiding smoking and maintaining a moderate exercise routine are also associated with later menopause and longer ovarian function.

When should women start thinking about ovarian aging?

Ovarian reserve begins declining from birth and accelerates sharply after age 30. Most interventions being studied -- rapamycin, AMH-based therapies, ovarian tissue cryopreservation -- are designed to be used before significant ovarian decline has occurred (typically before age 37-38). For lifestyle factors that influence menopause timing, the earlier the better. AMH testing in a woman's late 20s or early 30s can provide a baseline for tracking ovarian reserve over time.

Will it ever be possible to delay or prevent menopause?

Multiple clinical trials are actively exploring this. The VIBRANT trial at Columbia is testing rapamycin, Celmatix is developing AMH-mimicking drugs, and Dr. Oktay's ovarian tissue cryopreservation procedure aims to transplant younger tissue back into women approaching menopause. Whether these approaches will deliver the same health benefits as naturally delayed menopause remains an open question. Researchers are optimistic but realistic -- the science is genuine but still years from widespread clinical application.